Wockhardt Receives Warning Letter Over Sterility, Data Integrity Concerns

Drug Industry Daily
A A
Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls.

To View This Article:

Login

Subscribe To Drug Industry Daily